Certara (NASDAQ:CERT) Updates FY24 Earnings Guidance

Certara (NASDAQ:CERT) updated its FY24 earnings guidance on Wednesday. The company provided earnings per share guidance of $0.41-0.44 for the period, compared to the consensus earnings per share estimate of $0.41. The company issued revenue guidance of $380-385 million, compared to the consensus revenue estimate of $386.66 million. Certara also updated its FY 2024 guidance to 0.410-0.440 EPS.

Analysts Set New Price Targets

CERT has been the topic of several recent analyst reports. Robert W. Baird cut their price target on Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a research note on Tuesday. UBS Group raised shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 price target on the stock in a research report on Friday, September 27th. Finally, Barclays reduced their target price on Certara from $14.00 to $12.00 and set an “equal weight” rating on the stock in a report on Thursday. Six investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $15.92.

Certara Stock Performance

NASDAQ CERT traded up $0.04 during trading hours on Friday, reaching $11.03. The company’s stock had a trading volume of 1,081,810 shares, compared to its average volume of 786,430. The stock has a market cap of $1.77 billion, a PE ratio of -22.06, a PEG ratio of 4.88 and a beta of 1.51. The business has a 50-day simple moving average of $11.02 and a 200 day simple moving average of $13.70. Certara has a 52 week low of $9.99 and a 52 week high of $19.87. The company has a current ratio of 2.61, a quick ratio of 2.61 and a debt-to-equity ratio of 0.28.

Certara (NASDAQ:CERT) last released its quarterly earnings data on Wednesday, November 6th. The company reported $0.13 earnings per share for the quarter, topping analysts’ consensus estimates of $0.11 by $0.02. The business had revenue of $94.80 million for the quarter, compared to analysts’ expectations of $95.51 million. Certara had a negative net margin of 21.64% and a positive return on equity of 3.03%. The company’s revenue for the quarter was up 10.7% compared to the same quarter last year. During the same quarter last year, the company earned $0.06 EPS. Equities research analysts predict that Certara will post 0.27 earnings per share for the current fiscal year.

Insider Transactions at Certara

In other Certara news, insider Patrick F. Smith sold 5,409 shares of Certara stock in a transaction on Monday, October 7th. The stock was sold at an average price of $11.03, for a total transaction of $59,661.27. Following the sale, the insider now owns 50,091 shares of the company’s stock, valued at $552,503.73. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, insider Patrick F. Smith sold 5,409 shares of the stock in a transaction on Monday, October 7th. The stock was sold at an average price of $11.03, for a total value of $59,661.27. Following the completion of the transaction, the insider now owns 50,091 shares of the company’s stock, valued at approximately $552,503.73. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Leif E. Pedersen sold 51,224 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $11.29, for a total transaction of $578,318.96. Following the transaction, the insider now owns 99,704 shares in the company, valued at $1,125,658.16. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 2.39% of the company’s stock.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.